They burst onto the scene 4 years in the past and are taking on the pharmaceutical world. New GLP-1-based medication like Ozempic, Wegovy or Zepbound are stated to be a weight-loss sport changer and will drive massive pharma’s income for years to return. However they arrive with a hefty price ticket, whereas some 50 to 70 p.c of individuals taking GLP-1s undergo uncomfortable side effects. Charles Pellegrin asks Frederic Bizard, a well being economist and professor at ESCP Enterprise Faculty, who has probably the most to achieve from this pharma revolution.
Source link
The big business behind weight-loss drugs: Global market to hit $150 billion by 2035
